IDEAYA reports 57% eye preservation rate in darovasertib trial for primary uveal melanoma

Bitget2026/10/19 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IDEAYA Biosciences announced updated darovasertib results from three uveal melanoma trials for presentation at ESMO on October 24, 2026.
OptimUM-02 showed darovasertib with crizotinib delayed disease progression versus investigator-selected therapy across clinically relevant subgroups in previously untreated metastatic disease.
OptimUM-01 showed activity in previously untreated patients and those with prior treatment, supporting potential use across a broader metastatic population.
Neoadjuvant darovasertib in OptimUM-09 shrank primary tumors, helping patients preserve their eyes or reduce planned radiation exposure to critical eye structures.
Safety profiles remained manageable in OptimUM-01 and OptimUM-09.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190600PR_NEWS_USPR_____SF74488) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IDEAYA reports 57% eye preservation rate in darovasertib trial for primary uveal melanoma

You may also like

Crypto prices